Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
Status:
Withdrawn
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safety of candonilimab plus bevacizumab for patients with
advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.